Status:

COMPLETED

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study

Lead Sponsor:

University Hospital, Motol

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

Phase:

PHASE3

Brief Summary

This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patient are random...

Detailed Description

Randomized studies have shown that pre-treatment with atorvastatin may reduced periprocedural myocardial in patient with stable angina during elective PCI. These data provide evidence-based support fo...

Eligibility Criteria

Inclusion

  • stable angina in last month
  • indication for percutaneous coronary intervention
  • informed consent

Exclusion

  • acute coronary syndrome in last 14 days
  • renal insufficiency (creatinine more 150 µmol/l)
  • diseases severely limiting prognosis
  • immunosuppressive treatment
  • statin one month before randomization
  • occlusion of the coronary artery
  • previous participation in this study

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT00469326

Start Date

April 1 2005

End Date

December 1 2008

Last Update

January 27 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Cardiology, CardioVascular Center, University Hospital Motol

Prague, Czechia, 150 18

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study | DecenTrialz